Uso de inhibidores de la aromatasa para mejorar la estatura en niños: una revisión de la literatura
DOI:
https://doi.org/10.33448/rsd-v12i2.40181Palabras clave:
Inhibidores de la aromatasa; Trastornos del crecimiento; Crecimiento.Resumen
Introducción: La talla baja es actualmente uno de los motivos más frecuentes de búsqueda y derivación de pacientes a endocrinología pediátrica. Tal demanda se produce no sólo por los factores fisiológicos, sino también psicológicos involucrados. Objetivo: analizar la literatura específica sobre los inhibidores de la aromatasa y su uso en niños. Método: Se realizó una revisión narrativa de la literatura utilizando las bases de datos Pubmed, Google Scholar y UptoDate. Para la búsqueda se utilizaron los siguientes descriptores: “inhibidor de la aromatasa”, “niños” y “crecimiento”. Se seleccionaron artículos sobre el uso de inhibidores de la aromatasa en niños con talla baja. Se excluyeron los artículos que se enfocaron en el uso de inhibidores de aromatasa en el cáncer, el uso de inhibidores de aromatasa exclusivamente en el Síndrome de McCune Albright y que no fueron localizados en su totalidad. Se encontraron un total de 1028 producciones científicas, de las cuales 59 cumplieron con los criterios preestablecidos. Resultados y Discusión: La enzima aromatasa es una enzima del citocromo P450 y convierte precursores androgénicos en precursores estrogénicos. Los inhibidores de la aromatasa retrasan la senescencia del cartílago de crecimiento, y pueden estar indicados en niños con talla baja actual con repercusiones psicosociales o predicción inadecuada de la talla final. Según estudios publicados anteriormente, los inhibidores de la aromatasa han demostrado ser efectivos en el tratamiento de la baja estatura. Se concluye que el tratamiento con inhibidores de la aromatasa retrasa efectivamente la maduración ósea y mejora la talla adulta.
Citas
Bajpai, A., Simm, P. J., McPherson, S. J., Russo, V. C., Azar, W. J., Wark, J. D., Risbridger, G. P., & Werther, G. A. (2010). Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia. The Journal of endocrinology, 207(1), 27–34. https://doi.org/10.1677/JOE-10-0006
Berry J. (2005). Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clinical therapeutics, 27(11), 1671–1684. https://doi.org/10.1016/j.clinthera.2005.11.013
BIG 1-98 Collaborative Group, Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thürlimann, B., Paridaens, R., Smith, I., Mauriac, L., Forbes, J., Price, K. N., Regan, M. M., Gelber, R. D., & Coates, A. S. (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. The New England journal of medicine, 361(8), 766–776. https://doi.org/10.1056/NEJMoa0810818
Boeddinghaus, I. M., & Dowsett, M. (2001). Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. The Journal of steroid biochemistry and molecular biology, 79(1-5), 85–91. https://doi.org/10.1016/s0960-0760(01)00126-1
Burnett-Bowie, S. A., McKay, E. A., Lee, H., & Leder, B. Z. (2009). Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. The Journal of clinical endocrinology and metabolism, 94(12), 4785–4792. https://doi.org/10.1210/jc.2009-0739
Buzdar, A. U., Robertson, J. F., Eiermann, W., & Nabholtz, J. M. (2002). An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer, 95(9), 2006–2016. https://doi.org/10.1002/cncr.10908
Carel, J. C., Eugster, E. A., Rogol, A., Ghizzoni, L., Palmert, M. R., ESPE-LWPES GnRH Analogs Consensus Conference Group, Antoniazzi, F., Berenbaum, S., Bourguignon, J. P., Chrousos, G. P., Coste, J., Deal, S., de Vries, L., Foster, C., Heger, S., Holland, J., Jahnukainen, K., Juul, A., Kaplowitz, P., Lahlou, N., … Wit, J. M. (2009). Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics, 123(4), e752–e762. https://doi.org/10.1542/peds.2008-1783
Cavalli, A., Bisi, A., Bertucci, C., Rosini, C., Paluszcak, A., Gobbi, S., Giorgio, E., Rampa, A., Belluti, F., Piazzi, L., Valenti, P., Hartmann, R. W., & Recanatini, M. (2005). Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. Journal of medicinal chemistry, 48(23), 7282–7289. https://doi.org/10.1021/jm058042r
Cohen, P., Rogol, A. D., Deal, C. L., Saenger, P., Reiter, E. O., Ross, J. L., Chernausek, S. D., Savage, M. O., Wit, J. M., & 2007 ISS Consensus Workshop participants (2008). Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. The Journal of clinical endocrinology and metabolism, 93(11), 4210–4217. https://doi.org/10.1210/jc.2008-0509
Colussi, D. M., Parisot, C. Y., & Lefèvre, G. Y. (1998). Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor. Journal of clinical pharmacology, 38(8), 727–735. https://doi.org/10.1002/j.1552-4604.1998.tb04813.x
Damiani, D., & Damiani, D. (2007). Pharmacological management of children with short stature: the role of aromatase inhibitors. Jornal de pediatria, 83(5 Suppl), S172–S177. https://doi.org/10.2223/JPED.1699
Dunkel, L., & Wickman, S. (2003). Novel treatment of short stature with aromatase inhibitors. The Journal of steroid biochemistry and molecular biology, 86(3-5), 345–356. https://doi.org/10.1016/s0960-0760(03)00344-3
Dunkel L. (2006). Use of aromatase inhibitors to increase final height. Molecular and cellular endocrinology, 254-255, 207–216. https://doi.org/10.1016/j.mce.2006.04.031
Dunkel L. (2009). Update on the role of aromatase inhibitors in growth disorders. Hormone research, 71 Suppl 1, 57–63. https://doi.org/10.1159/000178040
Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002). Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20(3), 751–757. https://doi.org/10.1200/JCO.2002.20.3.751
Grumbach, M. M., & Auchus, R. J. (1999). Estrogen: consequences and implications of human mutations in synthesis and action. The Journal of clinical endocrinology and metabolism, 84(12), 4677–4694. https://doi.org/10.1210/jcem.84.12.6290
Hero, M., Norjavaara, E., & Dunkel, L. (2005). Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. The Journal of clinical endocrinology and metabolism, 90(12), 6396–6402. https://doi.org/10.1210/jc.2005-1392
Hero, M., Ankarberg-Lindgren, C., Taskinen, M. R., & Dunkel, L. (2006). Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. European journal of endocrinology, 155(3), 453–460. https://doi.org/10.1530/eje.1.02226
Hero, M., Mäkitie, O., Kröger, H., Nousiainen, E., Toiviainen-Salo, S., & Dunkel, L. (2009). Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Hormone research, 71(5), 290–297. https://doi.org/10.1159/000208803
Hero, M., Toiviainen-Salo, S., Wickman, S., Mäkitie, O., & Dunkel, L. (2010). Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 25(7), 1536–1543. https://doi.org/10.1002/jbmr.56
Herrmann, B. L., Saller, B., Janssen, O. E., Gocke, P., Bockisch, A., Sperling, H., Mann, K., & Broecker, M. (2002). Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. The Journal of clinical endocrinology and metabolism, 87(12), 5476–5484. https://doi.org/10.1210/jc.2002-020498
Jones, M. E., Boon, W. C., McInnes, K., Maffei, L., Carani, C., & Simpson, E. R. (2007). Recognizing rare disorders: aromatase deficiency. Nature clinical practice. Endocrinology & metabolism, 3(5), 414–421. https://doi.org/10.1038/ncpendmet0477
Kamdem, L. K., Liu, Y., Stearns, V., Kadlubar, S. A., Ramirez, J., Jeter, S., Shahverdi, K., Ward, B. A., Ogburn, E., Ratain, M. J., Flockhart, D. A., & Desta, Z. (2010). In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. British journal of clinical pharmacology, 70(6), 854–869. https://doi.org/10.1111/j.1365-2125.2010.03791.x
Lee, J. M., Appugliese, D., Coleman, S. M., Kaciroti, N., Corwyn, R. F., Bradley, R. H., Sandberg, D. E., & Lumeng, J. C. (2009). Short stature in a population-based cohort: social, emotional, and behavioral functioning. Pediatrics, 124(3), 903–910. https://doi.org/10.1542/peds.2008-0085
Leschek, E. W., Jones, J., Barnes, K. M., Hill, S. C., & Cutler, G. B., Jr (1999). Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. The Journal of clinical endocrinology and metabolism, 84(1), 175–178. https://doi.org/10.1210/jcem.84.1.5413
Linardi, A., Damiani, D., & Longui, C. A. (2017). The use of aromatase inhibitors in boys with short stature: what to know before prescribing?. Archives of endocrinology and metabolism, 61(4), 391–397. https://doi.org/10.1590/2359-3997000000284
Lønning, P., Pfister, C., Martoni, A., & Zamagni, C. (2003). Pharmacokinetics of third-generation aromatase inhibitors. Seminars in oncology, 30(4 Suppl 14), 23–32. https://doi.org/10.1016/s0093-7754(03)00305-1
Mauras, N., Attie, K. M., Reiter, E. O., Saenger, P., & Baptista, J. (2000). High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. The Journal of clinical endocrinology and metabolism, 85(10), 3653–3660. https://doi.org/10.1210/jcem.85.10.6906
Mauras, N., Bell, J., Snow, B. G., & Winslow, K. L. (2005). Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fertility and sterility, 84(1), 239–242. https://doi.org/10.1016/j.fertnstert.2005.02.012
Mauras, N., Gonzalez de Pijem, L., Hsiang, H. Y., Desrosiers, P., Rapaport, R., Schwartz, I. D., Klein, K. O., Singh, R. J., Miyamoto, A., & Bishop, K. (2008). Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. The Journal of clinical endocrinology and metabolism, 93(3), 823–831. https://doi.org/10.1210/jc.2007-1559
Mauras, N., Bishop, K., Merinbaum, D., Emeribe, U., Agbo, F., & Lowe, E. (2009). Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. The Journal of clinical endocrinology and metabolism, 94(8), 2975–2978. https://doi.org/10.1210/jc.2008-2527
Mauras N. (2011). Strategies for maximizing growth in puberty in children with short stature. Pediatric clinics of North America, 58(5), 1167–x. https://doi.org/10.1016/j.pcl.2011.07.007
Mauras, N., Ross, J. L., Gagliardi, P., Yu, Y. M., Hossain, J., Permuy, J., Damaso, L., Merinbaum, D., Singh, R. J., Gaete, X., & Mericq, V. (2016). Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature. The Journal of clinical endocrinology and metabolism, 101(12), 4984–4993. https://doi.org/10.1210/jc.2016-2891
Mauras, N., Ross, J., & Mericq, V. (2023). Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review. Endocrine reviews, 44(1), 1–13. https://doi.org/10.1210/endrev/bnac014
McGrath, N., & O'Grady, M. J. (2015). Aromatase inhibitors for short stature in male children and adolescents. The Cochrane database of systematic reviews, 2015(10), CD010888. https://doi.org/10.1002/14651858.CD010888.pub2
Mericq, M. V., Eggers, M., Avila, A., Cutler, G. B., Jr, & Cassorla, F. (2000). Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. The Journal of clinical endocrinology and metabolism, 85(2), 569–573. https://doi.org/10.1210/jcem.85.2.6343
Merke, D. P., Keil, M. F., Jones, J. V., Fields, J., Hill, S., & Cutler, G. B., Jr (2000). Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. The Journal of clinical endocrinology and metabolism, 85(3), 1114–1120. https://doi.org/10.1210/jcem.85.3.6462
Morishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995). Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. The Journal of clinical endocrinology and metabolism, 80(12), 3689–3698. https://doi.org/10.1210/jcem.80.12.8530621
Murai, K., Yamazaki, H., Nakagawa, K., Kawai, R., & Kamataki, T. (2009). Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems, 39(11), 795–802. https://doi.org/10.3109/00498250903171395
Murata, Y., Robertson, K. M., Jones, M. E., & Simpson, E. R. (2002). Effect of estrogen deficiency in the male: the ArKO mouse model. Molecular and cellular endocrinology, 193(1-2), 7–12. https://doi.org/10.1016/s0303-7207(02)00090-4
Neely, E. K., Kumar, R. B., Payne, S. L., Ranadive, S. A., & Suchet, D. I. (2014). Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. The Journal of clinical endocrinology and metabolism, 99(11), 4086–4093. https://doi.org/10.1210/jc.2014-2432
Patry, G., Jarvi, K., Grober, E. D., & Lo, K. C. (2009). Use of the aromatase inhibitor letrozole to treat male infertility. Fertility and sterility, 92(2), 829.e1–829.e8292. https://doi.org/10.1016/j.fertnstert.2009.05.014
Pedrosa, L. F., de Oliveira, J. M., Thomé, P. R. V., Kochi, C., Damiani, D., & Longui, C. A. (2017). Height Increment and Laboratory Profile of Boys Treated With Aromatase Inhibitors With or Without Growth Hormone. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 49(10), 778–785. https://doi.org/10.1055/s-0043-116944
Pfister, C. U., Martoni, A., Zamagni, C., Lelli, G., De Braud, F., Souppart, C., Duval, M., & Hornberger, U. (2001). Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharmaceutics & drug disposition, 22(5), 191–197. https://doi.org/10.1002/bdd.273
Precht, J. C., Schroth, W., Klein, K., Brauch, H., Krynetskiy, E., Schwab, M., & Mürdter, T. E. (2013). The letrozole phase 1 metabolite carbinol as a novel probe drug for UGT2B7. Drug metabolism and disposition: the biological fate of chemicals, 41(11), 1906–1913. https://doi.org/10.1124/dmd.113.053405
Queiroz, R.M.R. & Feferbaum, M. (2022). Metodologia da pesquisa em direito. Saraiva.
Robertson, K. M., O'Donnell, L., Jones, M. E., Meachem, S. J., Boon, W. C., Fisher, C. R., Graves, K. H., McLachlan, R. I., & Simpson, E. R. (1999). Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Proceedings of the National Academy of Sciences of the United States of America, 96(14), 7986–7991. https://doi.org/10.1073/pnas.96.14.7986
Rochira, V., Zirilli, L., Maffei, L., Premrou, V., Aranda, C., Baldi, M., Ghigo, E., Aimaretti, G., Carani, C., & Lanfranco, F. (2010). Tall stature without growth hormone: four male patients with aromatase deficiency. The Journal of clinical endocrinology and metabolism, 95(4), 1626–1633. https://doi.org/10.1210/jc.2009-1743
Saldanha, C. J., Duncan, K. A., & Walters, B. J. (2009). Neuroprotective actions of brain aromatase. Frontiers in neuroendocrinology, 30(2), 106–118. https://doi.org/10.1016/j.yfrne.2009.04.016
Santen, R. J., Brodie, H., Simpson, E. R., Siiteri, P. K., & Brodie, A. (2009). History of aromatase: saga of an important biological mediator and therapeutic target. Endocrine reviews, 30(4), 343–375. https://doi.org/10.1210/er.2008-0016
Saylam, B., Efesoy, O., & Cayan, S. (2011). The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertility and sterility, 95(2), 809–811. https://doi.org/10.1016/j.fertnstert.2010.09.021
Shulman, D. I., Francis, G. L., Palmert, M. R., Eugster, E. A., & Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee (2008). Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics, 121(4), e975–e983. https://doi.org/10.1542/peds.2007-2081
T'Sjoen, G. G., Giagulli, V. A., Delva, H., Crabbe, P., De Bacquer, D., & Kaufman, J. M. (2005). Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. The Journal of clinical endocrinology and metabolism, 90(10), 5717–5722. https://doi.org/10.1210/jc.2005-0982
Topor, L. S., Feldman, H. A., Bauchner, H., & Cohen, L. E. (2010). Variation in methods of predicting adult height for children with idiopathic short stature. Pediatrics, 126(5), 938–944. https://doi.org/10.1542/peds.2009-3649
Turner, K. J., Morley, M., Atanassova, N., Swanston, I. D., & Sharpe, R. M. (2000). Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. The Journal of endocrinology, 164(2), 225–238. https://doi.org/10.1677/joe.0.1640225
Turkistani, A., & Marsh, S. (2012). Pharmacogenomics of third-generation aromatase inhibitors. Expert opinion on pharmacotherapy, 13(9), 1299–1307. https://doi.org/10.1517/14656566.2012.687721
Wickman, S., Sipilä, I., Ankarberg-Lindgren, C., Norjavaara, E., & Dunkel, L. (2001). A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet (London, England), 357(9270), 1743–1748. https://doi.org/10.1016/S0140-6736(00)04895-9
Wickman, S., Kajantie, E., & Dunkel, L. (2003). Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. The Journal of clinical endocrinology and metabolism, 88(8), 3785–3793. https://doi.org/10.1210/jc.2002-021643
Wit, J., Hero, M. & Nunez, S. (2012) Aromatase inhibitors in pediatrics. Nat Rev Endocrinol 8, 135–147. https://doi.org/10.1038/nrendo.2011.161
Wit, J. M., Hero, M., & Nunez, S. B. (2011). Aromatase inhibitors in pediatrics. Nature reviews. Endocrinology, 8(3), 135–147. https://doi.org/10.1038/nrendo.2011.161
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Mauren Oliveira Cruz; Adriana Resende Milagres Saab
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
